How should diabetes mellitus be managed?

Management of Diabetes Mellitus

Start metformin immediately at diagnosis alongside lifestyle modifications (diet and exercise), then escalate systematically based on HbA1c response and comorbidities, with insulin reserved for severe hyperglycemia or treatment failure. 1

Initial Management Framework

Foundational Interventions (All Patients)

• Diet, exercise, and diabetes education form the absolute foundation of any diabetes treatment program and must be implemented from day one 1
• Target at least 150 minutes of moderate-intensity aerobic activity per week with resistance training twice weekly 1
• Individualized medical nutrition therapy, preferably delivered by a registered dietitian, is essential 1
• Comprehensive cardiovascular risk reduction must be a major focus alongside glycemic control 1

First-Line Pharmacotherapy

Metformin is the optimal first-line drug unless contraindicated or not tolerated 1

Key implementation details:

• Initiate at or soon after diagnosis if lifestyle intervention alone is insufficient 1
• Start at low dose with gradual titration to minimize gastrointestinal side effects 1
• Most cost-effective option with established cardiovascular benefits 1
• Can be continued with declining renal function down to GFR 30-45 mL/min with dose reduction 1

Escalation Algorithm Based on HbA1c

HbA1c 7-9%: Add Second Agent

If metformin monotherapy fails to achieve target after 3 months, add one of the following 1:

• Sulfonylurea
• Thiazolidinedione (TZD)
• DPP-4 inhibitor
• SGLT2 inhibitor
• GLP-1 receptor agonist
• Basal insulin

Selection should prioritize:

• Comorbid cardiovascular disease, heart failure, or chronic kidney disease (favor SGLT2 inhibitors or GLP-1 agonists) 1, 2, 3
• Hypoglycemia risk minimization 1
• Weight considerations (avoid agents causing weight gain when possible) 1
• Cost and patient preference 1

HbA1c ≥9%: Consider Dual Therapy or Insulin from Outset

Patients with HbA1c ≥9% have low probability of achieving target with monotherapy 1

• Start combination of two noninsulin agents or proceed directly to insulin 1

HbA1c ≥10-12% with Symptoms: Start Insulin Immediately

Insulin therapy is mandatory when: 1

• Significant hyperglycemic symptoms present
• Plasma glucose >300-350 mg/dL (16.7-19.4 mmol/L)
• HbA1c ≥10-12%
• Catabolic features or ketonuria present (indicating profound insulin deficiency)

Important caveat: Once symptoms resolve, insulin can often be tapered and transitioned to noninsulin agents unless type 1 diabetes is present 1

Insulin Therapy Specifics

Basal Insulin Initiation

Start with basal insulin alone unless patient is markedly hyperglycemic and symptomatic 1

Formulation selection:

• Long-acting analogs (glargine, detemir, degludec) preferred over NPH due to less nocturnal hypoglycemia and slightly less weight gain 1
• U-300 glargine or degludec have lower nocturnal hypoglycemia risk than U-100 glargine 1
• Starting dose: 0.1-0.2 units/kg/day (or 10 units) with individualized titration 1
• Continue metformin with basal insulin 1

Prandial Insulin Addition

Add prandial insulin when: 1

• Basal insulin achieves fasting glucose goals but HbA1c remains above target
• Progressive loss of insulin secretory capacity occurs

Preferred agents:

• Rapid-acting analogs (lispro, aspart, glulisine) dosed just before meals 1
• Superior postprandial control compared to regular human insulin 1

Essential Patient Education for Insulin Users

Mandatory education components: 1

• Glucose monitoring technique
• Insulin injection technique and storage
• Recognition and treatment of hypoglycemia
• "Sick day" management rules
• Matching insulin doses to carbohydrate, fat, and protein intake 1
• Correction dose calculations based on current glucose and trends 1

Type 1 Diabetes-Specific Management

Treat with multiple daily injections (≥3/day) or continuous subcutaneous insulin infusion from diagnosis 1

Key recommendations:

• Insulin analogs preferred over human insulins to minimize hypoglycemia 1
• Automated insulin delivery systems should be offered to all adults with type 1 diabetes 1
• Early continuous glucose monitoring recommended to improve outcomes and reduce hypoglycemia 1
• Education on carbohydrate counting and insulin dose adjustment is essential 1

Critical Pitfalls to Avoid

Do not delay insulin in patients not achieving glycemic goals with oral agents 1

Avoid overbasalization: Watch for basal insulin doses >0.5 units/kg or large bedtime-to-morning glucose differentials, which signal need for prandial insulin rather than more basal insulin 1

Do not use insulin as a threat or describe it as personal failure—emphasize its utility in disease progression 1

Reassess treatment plans every 3-6 months to ensure individualized goals are met and adjust for changing circumstances 1

Screen for and address hypoglycemia unawareness by raising glycemic targets temporarily to restore counterregulatory responses 1